Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT02764359

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

Conditions: Infection, Sepsis, Obesity

Sex: All
Ages: 18 Years – 99 Years
Healthy volunteers: No
Phase: NA
Enrollment: 76
Sponsor: CAMC Health System

Location: CAMC Health Systems Charleston West Virginia

Summary

Obesity alters the movement through the body of several antibiotics, including vancomycin. Based on literature to date, total body weight should be used to determine dosages and shorter dosing intervals may be needed. However, hospitals have different approaches to managing vancomycin in this patient population. The most common example is not exceeding a dose of 2,000mg of vancomycin at one time in these patients. However, some institutions including the Charleston Area Medical Center do not have a set maximum one time dose. To date, a study has not been done comparing two different dosing regimens in obese patients to determine if having a maximum dose cap is beneficial. This research study is attempting to add to the limited existing body of literature regarding vancomycin dosing in obese patients. The investigators hypothesize that optimizing the initial or loading vancomycin dose that obese patients receive will decrease the time to target concentrations. For this study, obese adult patients will be randomized to receive either 1) a loading dose of 20 mg/kg with a maximum dose up to 2,000mg OR 2) a loading dose of 20 mg/kg with a maximum dose of up to 4,000mg. The study's primary aim is to determine differences in the time needed to achieve target vancomycin concentrations and the occurrence of adverse events.

Eligibility Criteria

Inclusion Criteria: * Patients ≥18 years of age who present to the Charleston Area Medical Center-Memorial Hospital Emergency Department * Weight \>100kg * Infection requiring intravenous vancomycin and admission to Charleston Area Medical Center-Memorial Hospital Exclusion Criteria: * Any patient \0.5 mg/dL in SCr concentration in patients with a SCr of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02764359). StuddyBuddy aggregates publicly available trial information.